Topical Diacerein in Psoriasis Vulgaris

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE4

Enrollment: 60

Sponsor: Alaa Ashraf Muhammad Helal

Summary

The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group. Participants will: Be assigned to receive topical diacerein 1% or placebo twice daily for a treatment period of 2 months. Attend follow-up visits at Weeks 2, 4, 6, and 8. Undergo an additional evaluation one month after treatment cessation.

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years old of both genders. * Patients with mild chronic plaque psoriasis body surface area (BSA \< 10%) along with Psoriasis Area and Severity Index (PASI) score of \< 10, and/or Dermatology Life Quality Index (DLQI) score of \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07352306). StuddyBuddy aggregates publicly available trial information.